Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report.

导出 LinkOut

翻译打印收藏纠错

作者： Emma,Zattarin ^[1] ; Francesca,Ligorio ^[1] ; Federico,Nichetti ^[1] ; Giulia,Bianchi ^[1] ; Giuseppe,Capri ^[1] ; Filippo,de Braud ^[1]

作者单位： Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. ^[1] Oncology and Haemato-Oncology Department, University of Milan, Italy. ^[2]

关键词 Male breast cancer cyclin-dependent kinase 4/6 inhibitors endocrine treatment hormone receptor–positive breast cancer palbociclib

主题词成年人(Adult);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤, 男性(Breast Neoplasms, Male);人类(Humans);男(雄)性(Male);哌嗪类(Piperazines);预后(Prognosis);吡啶类(Pyridines);受体, 雌激素(Receptors, Estrogen);受体, 孕酮(Receptors, Progesterone);挽救疗法(Salvage Therapy)

DOI 10.1177/0300891620976981

PMID 33297845

发布时间 2022-04-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览7

Tumori

2021年107卷6期

NP15-NP19页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report.

Tumori

相似文献

Tumori

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report.

Tumori

相似文献

Tumori

相关期刊

检索历史清除